NCT05958082 Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer
| NCT ID | NCT05958082 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henry Ford Health System |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-01-01 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.
Eligibility Criteria
Inclusion Criteria: 1. Men, age greater than or equal to 18 years of age. 2. Men who racially identify as black or multiracial including black 3. Diagnosis of prostate cancer of any histology. 4. Must meet NCCN guidelines for germline testing 1. Men with very low, low or intermediate risk prostate per NCCN guidelines with a positive family history or intraductal histology. Family history here is considered significant if the patient has: * a first degree relative with prostate cancer or more than one first/second degree relative with prostate cancer, or * ≥3 cancers on same side of family, especially diagnoses ≤50 years of age: bile duct, breast, colorectal, endometrial, gastric, kidney, melanoma, ovarian, pancreatic, prostate (but not clinically localized Grade Group 1), small bowel, or urothelial cancer 2. Men with high-risk, very-high risk (per NCCN definitions of risk groups), lymph node positive, or metastatic prostate cancer independent of family history of histology. Exclusion Criteria: 1. Have had prior germline testing. 2. Have somatic genetic testing that is positive for a possible germline variant.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05958082 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05958082 currently recruiting?
Yes, NCT05958082 is actively recruiting participants. Contact the research team at chwang2@hfhs.org for enrollment information.
Where is the NCT05958082 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT05958082 clinical trial?
NCT05958082 is sponsored by Henry Ford Health System. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.